Kronos Bio (NASDAQ:KRON) reported quarterly losses of $(0.59) per share. This is a 11.32 percent decrease over losses of $(0.53) per share from the same period last year.
RBC Capital Maintains Outperform on Shift4 Payments, Lowers Price Target to $65
RBC Capital analyst Daniel Perlin maintains Shift4 Payments (NYSE:FOUR) with a Outperform and lowers the price target from $77 to $65.
